Details of Disease

General Information of Disease (ID: DIS9Y1NR)

• Disease Name: Hematologic tumour
• Disease Class: 2B33: Malignant haematopoietic neoplasm
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DIS9Y1NR: Hematologic tumour
• ICD Code: ICD-11: ICD-11: 2B33.Y
• Disease Identifiers:
  MONDO ID: MONDO_0004111
  UMLS CUI: C1335724
  MedGen ID: 233400

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 22 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
NiCord	DMTSURO	Phase 3	NA	[1]
Omidubicel	DMCIYNO	Phase 3	Cell therapy	[2]
Carlecortemcel-L	DM87P0F	Phase 2/3	NA	[3]
ARQ 531	DMRG0A3	Phase 2	NA	[4]
BP-100-1-01	DMKDGI8	Phase 2	NA	[5]
Darinaparsin	DMB4OFL	Phase 2	Small molecular drug	[6]
ECT-001	DMBOCAF	Phase 2	Cell therapy	[7]
MGTA-145	DM6ZMJT	Phase 2	Cell therapy	[8]
Saracatinib	DMBLHGP	Phase 2	Small molecular drug	[9]
AZD0466	DMWLZI6	Phase 1/2	Small molecular drug	[10]
BMS-986016	DMDCHM7	Phase 1/2	NA	[11]
MGD013	DMCVMUL	Phase 1/2	Antibody	[12]
TAK-007	DMJSQXT	Phase 1/2	CAR-NK Cell therapy	[13]
ABBV-621	DM90EO3	Phase 1	Small molecular drug	[14]
ABBV-CX-2029	DMUSOM9	Phase 1	Antibody drug conjugate	[15]
AMG 319	DM9P0NA	Phase 1	NA	[16]
IGM-8444	DMFJXDZ	Phase 1	Antibody	[17]
IMA 203	DMD9U5Q	Phase 1	Cell therapy	[18]
PRT543	DMHNZ3U	Phase 1	Small molecular drug	[19]
RG6076	DMO9BGI	Phase 1	Recombinant protein	[20]
SM09419	DM73YG5	Phase 1	Small molecular drug	[21]
VTR-297	DM9W0B6	Phase 1	Small molecular drug	[22]

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
GSK184072	DMMIR1K	Discontinued in Phase 2	Small molecular drug	[23]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] ClinicalTrials.gov (NCT02730299) Stem Cell Transplantation With NiCord (Omidubicel) vs Standard Umbilical Cord Blood in Patients With Leukemia, Lymphoma, and Myelodysplastic Syndrome (MDS). U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04260698) Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT00469729) Efficacy and Safety Study of StemEx, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT04728893) Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies (MK-1026-003). U.S. National Institutes of Health.
• [5] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032443)
• [6] ClinicalTrials.gov (NCT00421213) Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers. U.S. National Institutes of Health.
• [7] ClinicalTrials.gov (NCT04103879) US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia. U.S. National Institutes of Health.
• [8] ClinicalTrials.gov (NCT04762875) MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies. U.S. National Institutes of Health.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7731).
• [10] ClinicalTrials.gov (NCT04865419) Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies. U.S. National Institutes of Health.
• [11] ClinicalTrials.gov (NCT02061761) Safety Study of Anti-LAG-3 in CLL, HL, NHL and MM. U.S. National Institutes of Health.
• [12] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [13] Clinical pipeline report, company report or official report of Takeda.
• [14] ClinicalTrials.gov (NCT03082209) A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies. U.S. National Institutes of Health.
• [15] Clinical pipeline report, company report or official report of AbbVie.
• [16] ClinicalTrials.gov (NCT01300026) AMG 319 Lymphoid Malignancy FIH. U.S. National Institutes of Health.
• [17] ClinicalTrials.gov (NCT04553692) Study of IGM-8444 as a Single Agent and in Combination With Chemotherapy-based Regimens in Subjects With Solid Cancers. U.S. National Institutes of Health.
• [18] Clinical pipeline report, company report or official report of Immatics.
• [19] ClinicalTrials.gov (NCT03886831) A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies. U.S. National Institutes of Health.
• [20] Clinical pipeline report, company report or official report of Roche.
• [21] SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Acute Myeloid Leukemia Models. Blood; 2019,134 (Supplement_1):1377.
• [22] ClinicalTrials.gov (NCT03838926) Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies. U.S. National Institutes of Health.
• [23] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024569)